TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05443126: A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

Sponsor: Ellipses Pharma · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 265 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,172,940

Rescue Site Savings

+$1,439,220

Unlock Full NCT05443126 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05443126 Rescue Dossier →